LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.06 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.36M

Average 0.23M

LBRX Account Payables

Amounts the company owes suppliers for goods and services received.

LB Pharmaceuticals Inc Common StockNASDAQ: LBRX

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 1021.1% from a year ago

Account payables stood at $7.12M at the end of Q1 FY2026, up 1021.1% from a year earlier and up 234.7% from the prior quarter. Over 3 fiscal years it compounded at +138.9% a year.

Context

  • Account payables amounted to 1.8% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +1021.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.12M+234.7% QoQ
Last fiscal yearDec 2025
$2.13M-8.3% YoY
Year agoMar 2025
$635K+1021.1% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1021.1%——
1 year-8.3%——
3-year CAGR+138.9%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
2.13M USD
Year-over-year change
-8.3%
3-year CAGR
+138.9%

Account Payables vs competitors

How LBRX compares with its peers on the latest reported figures

  • LBRX's Mar 2026 account payables of $7.12M is the 4th highest of the 10 companies compared; the peer median is $5.21M.
  • Its year-over-year change of +1021.1% is the highest of 10, against a peer median of +14.3%.
  • Account payables amounts to 1.8% of total assets for LBRX, versus a peer median of 1.0%.
LBRX Competitors Peer median
Account Payables for LBRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACADACADIA Pharmaceuticals Inc.Sep 2026$16.33M -24.9%-5.1%0.9%
DNLIDenali Therapeutics Inc.Jun 2026$11.81M +8.9%+6.1%1.0%
DFTXDefinium Therapeutics, Inc.Sep 2026$9.28M +14.3%+36.3%0.9%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$7.12M +1021.1%+138.9%1.8%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$6.56M +206.7%+42.4%1.3%
GHRSGH Research PLCMar 2026$5.21M +9.2%+26.4%1.9%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$5.06M +380.7%-22.1%3.3%
ANROAlto Neuroscience, Inc.Mar 2026$3.37M +143.4%+5.4%1.2%
NERVMinerva Neurosciences, Inc.Jun 2026$1.45M +61.5%-13.0%0.0%
MPLTMapLight Therapeutics, Inc.Mar 2026$0 -100.0%—0.0%
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding LBRX) $5.21M+14.3%+5.7%1.0%

Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents21.4M14.98M22.98M250.17M
Short-term Investments028.31M5.02M45.04M
Net Receivables0000
Inventory0000
Other Current Assets9K26K132K11.24M
Total Current Assets21.49M45.63M28.88M308.43M
Property, Plant & Equipment (Net)3K23K4.16M3.73M
Goodwill0000
Intangible Assets0000
Long-term Investments000770K
Tax Assets0000
Other Non-current Assets00498K0
Total Non-current Assets3K23K4.66M4.5M
Total Assets21.49M45.66M33.53M312.93M
Account Payables156K1.39M2.32M2.13M
Short-term Debt000730K
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities221K798K2.24M2.91M
Total Current Liabilities469K2.61M8.11M7.44M
Long-term Debt24.15M000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities25.69M77.52M116.76M1.34M
Total Non-current Liabilities49.84M77.52M119.98M4.18M
Total Liabilities50.3M80.13M128.09M11.62M
Common Stock1K1K1K3K
Retained Earnings(34.95M)(41.22M)(104.32M)(129.53M)
Accumulated OCI0274K111K168K
Other Stockholders Equity0000
Minority Interest0000
Total Equity(28.81M)(34.47M)(94.55M)301.31M
Total Debt24.15M03.7M3.57M
Net Debt2.74M(14.98M)(19.28M)(246.6M)

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Intrinsic Alpha fair value

Locked

Current Price

$40.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.